OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Ip on the Importance of NGS Testing in Hematologic Malignancies

January 5th 2024

Andrew Ip, MD, discusses findings from a study on the use of next-generation sequencing of flow cytometry CD markers and machine learning as a replacement to flow cytometry analysis for the diagnosis of hematologic neoplasms.

Dr Bartsch on the TUXEDO-1 Trial of T-DXd in HER2+ Breast Cancer With Brain Metastases

January 5th 2024

Rupert Bartsch, MD, discusses findings from the final analysis of the phase 2 TUXEDO-1 trial of trastuzumab deruxtecan in patients with HER2-positive breast cancer with active brain metastases.

Dr Ailawadhi on Iopofosine I-131 in Waldenström Macroglobulinemia

January 5th 2024

Sikander Ailawadhi, MD, oncologist, Department of Hematology, CAR T-Cell Therapy Program, Mayo Clinic, discusses how the investigational agent iopofosine I-131 may address unmet needs for patients with Waldenström macroglobulinemia.

Dr He on the Evaluation of Camrelizumab Plus Rivoceranib in Unresectable HCC

January 4th 2024

Aiwu Ruth He, MD, PhD, discusses the evaluation of camrelizumab plus rivoceranib in unresectable hepatocellular carcinoma.

Dr Necchi on the Efficacy of TAR-200 Monotherapy in BCG-Unresponsive NMIBC

January 4th 2024

Andrea Necchi, MD, discusses results from the phase 2b SunRISe-1 trial of TAR-200 in patients with Bacillus Calmette-Guérin (BCG)–unresponsive, high-risk, non–muscle-invasive bladder cancer.

Dr Leslie on the Significance of the FDA Approval of Pirtobrutinib in Pretreated CLL and SLL

January 4th 2024

Lori A. Leslie, MD, discusses the significance of the FDA approval of pirtobrutinib for patients with pretreated chronic lymphocytic leukemia or small lymphocytic lymphoma.

Dr Hill on the Use of Carfilzomib With R-CHOP in DLBCL

January 4th 2024

Brian T. Hill, MD, PhD, discusses the final results from a phase 1/2 trial of carfilzomib given with R-CHOP in the frontline setting for patients with non-germinal center diffuse large B-cell lymphoma.

Dr Sallman on the Rationale For Investigating Fedratinib in MDS/MPN Overlap Syndromes

January 4th 2024

David A. Sallman, MD, discusses the rationale for conducting a phase 2, multi-institutional, investigator-initiated clinical trial on the use of fedratinib in patients with myelodysplastic syndromes/myeloproliferative neoplasm overlap syndromes and chronic neutrophilic leukemia.

Dr Gerds on the Importance of Evaluating Selinexor in JAK Inhibitor–Naive Myelofibrosis

January 4th 2024

Aaron Gerds, MD, discusses the importance of evaluating the efficacy and safety of selinexor in patients with JAK inhibitor–naive myelofibrosis, as assessed in the phase 1/3 XPORT-MF-034 trial.

Dr Sammons on Treating Patients With Breast Cancer Who Present With Brain Metastases

January 3rd 2024

Sarah Sammons, MD, discusses the goals of treating patients with breast cancer who present with active vs stable brain metastasis.

Dr Gold on the Benefit of Targeted Therapies in Mutated Lung Cancers

January 3rd 2024

Kathryn A. Gold, MD, discusses the benefit of targeted therapies in patients with mutated lung cancers.

Dr Kim on a Case Study of a Patient With HCC

January 3rd 2024

Richard Kim, MD, discusses a case study of a patient who presented with hepatocellular carcinoma, detailing the steps that were taken upon diagnosis.

Dr Richardson on the Efficacy of Selinexor in TP53 Wild-Type Endometrial Cancer

January 3rd 2024

Debra L. Richardson, MD, FACS, FACOG, discusses the impact of selinexor’s mechanism of action on the agent’s clinical efficacy in patients with TP53 wild-type advanced or recurrent endometrial cancer.

Dr Feldman on Updated Findings From the TRANSCEND CLL 004 Trial in CLL/SLL

January 2nd 2024

Tatyana Feldman, MD, discusses updated safety and efficacy data from the phase 1/2 TRANSCEND CLL 004 trial in patients with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.

Dr Leslie on the Clinical Benefit of Axi-Cel in Elderly Patients With R/R LBCL

January 2nd 2024

Lori A. Leslie, MD, discusses the efficacy and safety of second-line axicabtagene ciloleucel in elderly patients with high-risk, relapsed/refractory large B-cell lymphoma.

Dr Jhaveri on the Rationale for the ELAINE-3 Trial in ESR1-Mutant ER+/HER2– Breast Cancer

December 21st 2023

Komal Jhaveri, MD, FACP, discusses the rationale for investigating lasofoxifene alongside abemaciclib in ESR1-mutated estrogen receptor–positive, HER2-negative metastatic breast cancer.

Dr Huppert on Sequential Treatment with T-DXd and Sacituzumab Govitecan in HER2-Low Breast Cancer

December 21st 2023

Laura A. Huppert, MD, discusses the impact of sequential treatment with fam-trastuzumab deruxtecan-nxki and sacituzumab govitecan-hziy on outcomes in patients with HER2-low metastatic breast cancer, according to findings from a retrospective analysis.

Dr Rini on the FDA Approval of Belzutifan in Advanced RCC

December 21st 2023

Brian I. Rini, MD, FASCO, discusses the significance of the FDA approval of belzutifan for the treatment of patients with advanced renal cell carcinoma

Dr Patel on the Exploration of Sacituzumab Govitecan in NSCLC

December 20th 2023

Sandip P. Patel, MD, discusses the utilization of sacituzumab govitecan in non–small cell lung cancer, highlighting trials in which the TROP2-directed antibody-drug conjugate is being evaluated in this patient population.

Dr Niikura on T-DXd in Patients With HER2+ Breast Cancer With Brain Metastases and Leptomeningeal Disease

December 20th 2023

Naoki Niikura, MD, PhD, discusses the impact of treatment with trastuzumab deruxtecan in patients with HER2-positive breast cancer with brain metastases and/or leptomeningeal disease, as evaluated in the real-world ROSET-BM study in Japan.